Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 11:31 ET | Source: Research and Markets

Tumor Microenvironment Market to Reach Over $2.7 Billion by 2030 - Rising Demand for Personalized Oncology Therapies and Next-Gen Immunotherapies Driving the Industry

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Tumor Microenvironment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The tumor microenvironment (TME) market has...
March 30, 2026 05:15 ET | Source: Research and Markets

Trends and Opportunities in the Chemotherapy-At-Home Services Market, 2026-2030: Total Revenue to Grow by $1 Billion, Led by CVS Health, Optum, and Fresenius Kabi

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Chemotherapy At Home Services Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers a comprehensive analysis,...
March 17, 2026 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer
January 27, 2026 16:35 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering

OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...
January 21, 2026 23:20 ET | Source: Levin Papantonio

Plaintiffs’ Evidence Will Be Heard in Cases Alleging J&J’s Talc Products Caused Women’s Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Judge gives nod to the admissibility of plaintiffs' expert testimony supporting general causation in J&J talc MDL.
December 22, 2025 06:00 ET | Source: Biosplice Therapeutics, Inc.

Biosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian Cancer

Biosplice Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in Ovarian Cancer
December 15, 2025 10:00 ET | Source: CancerNetwork

New research in ONCOLOGY® identifies gaps between gynecologic cancer disease burden and clinical trial availability at UCLA Jonsson Comprehensive Cancer Center

New research in ONCOLOGY finds major gaps between cancer incidence and clinical trial enrollment, highlighting urgent needs for equity and better access.
December 01, 2025 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series

OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...
November 27, 2025 08:20 ET | Source: Research and Markets

Her3-Targeted Immunotherapies Pipeline and Competitive Intelligence Report

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Her3-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
November 27, 2025 08:16 ET | Source: Research and Markets

Mesothelin-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of Mesothelin-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...